Content

Six Editorial Board Members of Hepatoma Research Included in Clarivate's 2023 "Highly Cited Researchers" List – Congratulations!

Published on: 7 Dec 2023 Viewed: 263

On November 15, 2023, Clarivate unveiled the "Highly Cited Researchers in 2023" list, recognizing exceptional individuals affiliated with universities, research institutes, and commercial organizations for their significant contributions to advancing their respective fields. The selection process involved using the Web of Science™ citation index data, analyzed meticulously by bibliometric experts and data scientists at Clarivate’s Institute for Scientific Information (ISI)™. Honorees were chosen based on highly cited papers published over an 11-year span (January 2012 - December 2022), totaling 188,500 influential papers across various disciplines. This thorough evaluation acknowledged 6,849 researchers and 7,125 individuals, solidifying their positions among the world's most cited scientists for the current year.

Delightedly, six esteemed Editorial Board members of Hepatoma Research are named to the list: Honorary Editor-in-Chief Prof. Shukui Qin, Associate Editor Prof. Jia Fan, Editorial Board members Prof. Antonio Bertoletti, Prof. William C. Cho, Prof. Richard S. Finn, and Prof. Amedeo Lonardo.

Prof. Antonio Bertoletti

1.jpg

Highly Cited Researcher in the field of Cross-Field - 2023

Emerging Infectious Disease Program, Duke-NUS Medical School, Singapore, Singapore.

EASL International Recognition Award Recipient 2023, an expert in the field of viral hepatitis, with a specific interest in the immunopathogenesis of HBV infection, and a Full Professor at the Emerging Viral Disease Program at Duke-NUS Medical School. Prof. Antonio Bertoletti also holds an Adjunct Position at the Singapore Immunology Network, (A*STAR). He won the Singapore Translational Research Awards for two consecutive terms (2013 and 2018). In 2015, he founded Lion TCR Pte (http://liontcr.com), a biotech company developing immune-based treatments for virus-related cancers (HBV-HCC and EBV-related malignancies) and chronic viral infections. The company’s immune therapy utilizes T cell receptors-engineered T cells targeting viral antigens expressed in cancer cells. The company has been the first to initiate and run clinical trials (Phase I and II) for the treatment of HBV-related HCC relapses in liver transplant patients and in primary HCC in Singapore and China. At present, he is Chairman of the Board and a major shareholder. His current research is focused on the development of new immunology-based therapies (TCR-redirected T cells) for the treatment of HBV chronic infection and hepatocellular carcinoma and on the characterization of antiviral Immunity in chronic HBV patients. In the last two years, after the start of the COVID-19 pandemic, his laboratory has been actively involved in the characterization of SARS-COV2 specific T cell immune response (Le Bert et al., Nature 2020, 584: 457-62) in COVID-19 and SARS convalescent and healthy individuals.

Prof. Amedeo Lonardo

2.jpg

Highly Cited Researcher in the field of Cross-Field - 2023

Operating Unit of Metabolic Syndrome, Azienda Ospedaliero-Universitaria di Modena, Ospedale Civile di Baggiovara, Modena, Italy.

Graduated from the University of Campania "Luigi Vanvitelli" in Italy, specializing in Gastroenterology and Digestive Endoscopy, followed by specializations in Pediatrics and Internal Medicine at the University of Modena and Reggio Emilia. Since April 1988, Prof. Amedeo Lonardo has carried out his entire professional career in Modena, first at the Sant'Agostino Hospital, then at the Policlinico, and later at the Baggiovara Civil Hospital since its opening. In 2017, Prof. Lonardo obtained his qualification for National Scientific Qualification in Internal Medicine and Gastroenterology. His primary research focuses on the metabolic pathology of the liver, i.e., the "fatty liver", which is an indicator but also the cause of cardio-metabolic alterations such as diabetes, hypertension, and dyslipidemia. He has extensively explored the clinical manifestations, associations, and complications of fatty liver. Over the past 10 years, he has been ranked among the top 0.012% of scholars studying "fatty liver" worldwide (Expertscape). Additionally, he was on the board of the scientific journal World Journal of Gastroenterology from 2018-2021. He was recognized as an exceptional reviewer for Preventing Chronic Disease in 2021. Furthermore, he has been ranked the top reviewer in Clinical Medicine since 2018, according to the Web of Science.

Prof. Jia Fan

3.jpg

Highly Cited Researcher in the field of Clinical Medicine – 2023

Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China.

Academician of Chinese Academy of Sciences; President of Zhongshan Hospital affiliated to Fudan University; Chairman of the Shanghai Institute of Liver Diseases; Director of the Shanghai Clinical Research Center for Liver Cancer; Director of the Liver Cancer Institute, Fudan University; Director of the Department of Oncology and Organ Transplantation Center, Zhongshan Hospital, Fudan University; Director of the Fudan Zhongshan Cancer Center; Chairman of the Expert Committee on Quality Control of Liver Cancers, National Cancer Center; Association President of Chinese College of Surgeons; President of the Chinese Society of Liver Surgeons (CSLS); Vice Chairman of CSCO; Executive Director of the Chinese Medical Association; Fellow of the American College of Surgeons (FACS); Member of the American Society of Clinical Oncology (ASCO); Member of the American Society of Surgical Oncology (SSO); Chairman of the Compilation Expert Committee on Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2017 Edition, 2019 Edition), Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition).

Prof. William C. Cho

4.jpg

Highly Cited Researcher in the field of Cross-Field - 2023

Department of Clinical Oncology, Queen Elizabeth Hospital Hong Kong, Hong Kong, China.

Biomedical Scientist in Queen Elizabeth Hospital. Prof. William C. Cho’s main research interests involve utilizing high-throughput technologies to identify biomarkers for cancer diagnosis, treatment prediction, and prognostication. He is a Chartered Scientist granted by the Science Council (UK), a Registered Chinese Medicine Practitioner (HK), a Guest Professor of a number of Universities, and a Fellow Member of several institutes, including the Institute of Biomedical Science (UK), Hong Kong Institute of Biomedical Science, and Hong Kong Society for Molecular Diagnostic Sciences. He serves as the Editor-in-Chief, Editor, and Associate Editor of several international medical journals. Prof. Cho is also an internationally renowned grant reviewer of the Hope Funds for Cancer Research (USA), Cancer Research (UK), MRC Research Grant (UK), Health Research Board (Ireland), Science Foundation (Ireland), Istituto Toscano Tumori (Firenze), The Foundation Fournier-Majoie for Innovation (Brussels), National Medical Research Council (Singapore), The Medical Research Council (South Africa), Academia Sinica Investigator Award (Taiwan), etc.

Prof. Richard S. Finn

5.jpg

Highly Cited Researcher in the field of Clinical Medicine – 2023

Department of Medicine, Division of Hematology/ Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Professor of clinical medicine in the Division of Hematology/Oncology at the UCLA David Geffen School of Medicine and the Director of the Signal Transduction Program in the Jonsson Comprehensive Cancer Center at UCLA in Los Angeles, CA. Prof. Richard S. Finn currently splits his time between patient care and laboratory and clinical research. His research interests revolve around the development of molecular targeted agents and biomarkers in liver cancer and breast cancer. Prof. Finn has been actively involved as principal and sub-investigator in trials exploring the use of targeted therapies in breast and hepatocellular cancers. He has a particular interest in identifying predictive markers of response to novel therapeutics. Prof. Finn has played a pivotal role in developing several novel therapeutics in cancer medicine, leading to transformative advancements that have reshaped cancer treatment practices. He is a member of ASCO, the American Association of Cancer Research (AACR), and the European Society of Medical Oncology (ESMO), and has previously served as the president of the International Liver Cancer Association (ILCA). Currently, he is also on the Editorial Board of Clinical Cancer Research.

Prof. Shukui Qin

6.jpg

Highly Cited Researcher in the field of Clinical Medicine – 2023

Cancer Centre of Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.

The Deputy Director of People's Liberation Army (PLA) 81 Hospital (Nanjing, China), Director of Cancer Center of Chinese PLA, and Director of National Drug Clinical Trial Agency of PLA 81 Hospital. Prof. Shukui Qin serves as the Executive Member of the Asian Clinical Oncology Society (ACOS), Chair of the Chinese Society of Clinical Oncology (CSCO), Council Member of the PLA Medical Science Commission (and the Executive Member of its oncology society), Member of the Oncology Branch of Chinese Medical Association, Expert Committee Member of National Tumor Standardized Diagnosis and Treatment of Ministry of Health (and also the leader of the Liver Cancer Expert Panel and Cancer Pain Expert Panel), Vice President of Beijing Xisike Clinical Oncology Research Foundation, and Member of Chinese Anti-cancer Association (CACA) (and the Vice Chairman of the Committee of Rehabilitation and Palliative Care affiliated to CACA). After decades of clinical practice and scientific research, Prof. Qin has accumulated rich experiences in the medical treatment of gastrointestinal cancers and their bone metastases. Prof. Qin has published over 400 articles in peer-reviewed journals. He has been granted a number of professional awards at the ministerial and provincial levels (including four first-class prizes, two second-class prizes, seven third-class prizes, and two fourth-class prizes). He is granted special government allowance by the State Council of China and the PLA. Currently, he is the Editor-in-Chief of two highly-rated journals (Journal of Clinical Oncology and Clinical Oncology Tribune) in China.

The Editorial Office of Hepatoma Research extends heartfelt congratulations to these esteemed recipients! We are committed to collaborating with these scholars to further elevate the impact and standing of Hepatoma Research and build it into an influential international journal in the field.

For the full list of Highly Cited Researchers 2023: https://clarivate.com/highly-cited-researchers/?campaignname=Highly_Cited_Researchers_Retention_AG_Global_2023&campaignid=7014N000001zmyjQAA&utm_campaign=Highly_Cited_Researchers_Retention_AG_Global_2023&utm_source=earned_coverage&utm_medium=press

Editor: Eric Zhang      
Language Editor: Catherine Yang      
Respectfully Submitted by the Editorial Office of Hepatoma Research

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/